Interleukin-35: An emerging player in the progression of liver diseases - 16/01/21
pages | 6 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | IL-35 exerts suppressive effects in immune related diseases and hepatic disorders. |
• | IL-35 plays diverse roles in acute hepatitis patients and chronic virus carriers. |
• | IL-35 is crucial in liver fibrosis and cirrhosis which imply a new therapy target. |
• | Roles of IL-35 in liver cancers are controversial, more researches still needed. |
Summary |
Interleukin-35(IL-35), a newly identified immunosuppressive cytokine, has recently been shown to play a significant role in the progression of various autoimmune diseases and malignant tumors. The liver is the largest organ in the body and is generally regarded as an important lymphoid organ by an increasing number of immunologists. A number of reports have demonstrated that IL-35 plays essential roles in maintaining the immune homeostasis of the liver microenvironment. This review summarizes the existing studies of IL-35 in liver diseases, including viral hepatitis, immune liver injury, liver cirrhosis and carcinoma. We aimed to provide a comprehensive overview of the vital roles of IL-35 in hepatic damage and explore new alternative therapeutic targets for these diseases.
Le texte complet de cet article est disponible en PDF.Abbreviations : IL, EBI3, Treg, CTLA-4, DCs, pDCs, AHB, HCC, HNF4a, iCCA, dnTGFβRII, IFN, HAV, HBV, ASC, HCV, HDV, HEV, MSCs, d-GalN, LPS, Con A, LC, PBC, UDCA
Keywords : Interleukin-35, Liver immune, Hepatitis, Hepatocellular carcinoma
Plan
Vol 45 - N° 1
Article 101518- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?